|
1
|
Zbar B, Klausner R and Linehan WM:
Studying cancer families to identify kidney cancer genes. Annu Rev
Med. 54:217–233. 2003.
|
|
2
|
Ljungberg B, Hanbury DC, Kuczyk MA, et al:
Renal cell carcinoma guideline. Eur Urol. 51:1502–1510. 2007.
|
|
3
|
Escudier B, Eisen T, Stadler WM, et al:
Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J
Med. 356:125–134. 2007.
|
|
4
|
Motzer RJ, Hutson TE, Tomczak P, et al:
Sunitinib versus interferon alfa in metastatic renal-cell
carcinoma. N Engl J Med. 356:115–124. 2007.
|
|
5
|
Kim WY and Kaelin WG: Role of VHL gene
mutation in human cancer. J Clin Oncol. 22:4991–5004. 2004.
|
|
6
|
Artavanis-Tsakonas S, Rand MD and Lake RJ:
Notch signaling: cell fate control and signal integration in
development. Science. 284:770–776. 1999.
|
|
7
|
Bettenhausen B, Hrabĕ de Angelis M, Simon
D, Guenet JL and Gossler A: Transient and restricted expression
during mouse embryogenesis of Dll1, a murine gene closely related
to Drosophila Delta. Development. 121:2407–2418. 1995.
|
|
8
|
Ellisen LW, Bird J, West DC, et al: TAN-1,
the human homolog of the Drosophila notch gene, is broken by
chromosomal translocations in T lymphoblastic neoplasms. Cell.
66:649–661. 1991.
|
|
9
|
Miele L, Golde T and Osborne B: Notch
signaling in cancer. Curr Mol Med. 6:905–918. 2006.
|
|
10
|
Qi R, An H, Yu Y, et al: Notch1 signaling
inhibits growth of human hepatocellular carcinoma through induction
of cell cycle arrest and apoptosis. Cancer Res. 63:8323–8329.
2003.
|
|
11
|
Shi W and Harris AL: Notch signaling in
breast cancer and tumor angiogenesis: cross-talk and therapeutic
potentials. J Mammary Gland Biol Neoplasia. 11:41–52. 2006.
|
|
12
|
Sjölund J, Johansson M, Manna S, et al:
Suppression of renal cell carcinoma growth by inhibition of Notch
signaling in vitro and in vivo. J Clin Invest. 118:217–228.
2008.
|
|
13
|
Ai Q, Ma X, Huang Q, et al: High-level
expression of Notch1 increased the risk of metastasis in T1 stage
clear cell renal cell carcinoma. PLoS One. 7:e350222012.
|
|
14
|
Sun S, Du R, Gao J, et al: Expression and
clinical significance of Notch receptors in human renal cell
carcinoma. Pathology. 41:335–341. 2009.
|
|
15
|
Wu K, Xu L, Zhang L, Lin Z and Hou J: High
Jagged1 expression predicts poor outcome in clear cell renal cell
carcinoma. Jpn J Clin Oncol. 41:411–416. 2010.
|
|
16
|
Massi D, Tarantini F, Franchi A, et al:
Evidence for differential expression of Notch receptors and their
ligands in melanocytic nevi and cutaneous malignant melanoma. Mod
Pathol. 19:246–254. 2006.
|
|
17
|
Weng AP and Aster JC: Multiple niches for
Notch in cancer: context is everything. Curr Opin Genet Dev.
14:48–54. 2004.
|
|
18
|
Weng AP, Ferrando AA, Lee W, et al:
Activating mutations of NOTCH1 in human T cell acute lymphoblastic
leukemia. Science. 306:269–271. 2004.
|
|
19
|
Ridgway J, Zhang G, Wu Y, et al:
Inhibition of Dll4 signalling inhibits tumour growth by
deregulating angiogenesis. Nature. 444:1083–1087. 2006.
|
|
20
|
Zeng Q, Li S, Chepeha DB, et al: Crosstalk
between tumor and endothelial cells promotes tumor angiogenesis by
MAPK activation of Notch signaling. Cancer Cell. 8:13–23. 2005.
|
|
21
|
Xu L, Zhu Y, Xu J, et al: Notch1
activation promotes renal cell carcinoma growth via PI3K/Akt
signaling. Cancer Sci. 103:1253–1258. 2012.
|
|
22
|
Lazarov VK, Fraering PC, Ye W, Wolfe MS,
Selkoe DJ and Li H: Electron microscopic structure of purified,
active gamma-secretase reveals an aqueous intramembrane chamber and
two pores. Proc Natl Acad Sci USA. 103:6889–6894. 2006.
|
|
23
|
Wei P, Walls M, Qiu M, et al: Evaluation
of selective gamma-secretase inhibitor PF-03084014 for its
antitumor efficacy and gastrointestinal safety to guide optimal
clinical trial design. Mol Cancer Ther. 9:1618–1628. 2010.
|
|
24
|
Rasul S, Balasubramanian R, Filipović A,
Slade MJ, Yagüe E and Coombes RC: Inhibition of gamma-secretase
induces G2/M arrest and triggers apoptosis in breast cancer cells.
Br J Cancer. 100:1879–1888. 2009.
|
|
25
|
Park SJ, Lee JL, Park I, et al:
Comparative efficacy of sunitinib versus sorafenib as first-line
treatment for patients with metastatic renal cell carcinoma.
Chemotherapy. 58:468–474. 2012.
|
|
26
|
Banks RE, Tirukonda P, Taylor C, et al:
Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene
alterations and relationship with clinical variables in sporadic
renal cancer. Cancer Res. 66:2000–2011. 2006.
|
|
27
|
Yao M, Yoshida M, Kishida T, et al: VHL
tumor suppressor gene alterations associated with good prognosis in
sporadic clear-cell renal carcinoma. J Natl Cancer Inst.
94:1569–1575. 2002.
|
